C
Indication details
- Control Arm
- Ipilimumab 10mg/kg
- Treatment setting
- Adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
- Tumour Type
-
Melanoma
- Tumour Sub-type
- Cutaneous Melanoma
- Tumour Stage
- Adjuvant
- Trial Name
- CheckMate 238
- NCT Number
- NCT02388906
- Trial Phase
- Phase III
Approval details
- EMA Approval
- EMA (June 2018) EC decision October 2018
- Comment
- EMA treatment setting updated in July 2023
Primary Outcome(s)
- Primary Outcome(s)
- RFS
- Evaluated Outcome
- RFS
- Form(s)
- Form 1
Outcome Data
- OS Control
- 4-years 76.6%
- OS Gain
- 4-years 1.3%
- OS HR
- 0.87 (0.66-1.14) Not significant
- RFS Control
- 24.1 months 4-year 41.2%
- RFS Gain
- 28.3 months 4-year 10.5%
- RFS HR
- 0.71 (0.60-0.86)
Adjustments
- QoL Comment
-
QoL data pending
- Toxicity Comment
-
Fewer treatment-related grade 3 or 4 AEs: 14.4% versus 45.9%
Fewer treatment discontinuation due to treatment-related AEs: 7.7% versus 41.7%
Final Score (after adjustments)
- Final curative score
-
C
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 174
- Scorecard version
- 1
- Issue date
- 09.06.2020
- Last update
- 24.07.2023
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.